Relationship between endoscopic mucosal healing and histologic inflammation during remission maintenance phase in ulcerative colitis: a retrospective study

被引:29
|
作者
Kanazawa, Mimari [1 ]
Takahashi, Fumiaki [1 ,2 ]
Tominaga, Keiichi [1 ]
Abe, Keiichiro [1 ]
Izawa, Naoya [1 ]
Fukushi, Koh [1 ]
Nagashima, Kazunori [1 ]
Kanamori, Akira [1 ]
Takenaka, Kazuhiro [1 ]
Sugaya, Takeshi [1 ]
Iijima, Makoto [1 ]
Takada, Atsuko [3 ]
Imai, Yasuo [3 ]
Hiraishi, Hideyuki [1 ]
Irisawa, Atsushi [1 ]
机构
[1] Dokkyo Med Univ, Dept Gastroenterol, 880 Kitakobayashi, Shimotsuga, Tochigi 3210293, Japan
[2] Japanese Red Cross Ashikaga Hosp, Dept Internal Med, Ashikaga, Tochigi, Japan
[3] Dokkyo Med Univ, Dept Diagnost Pathol, Shimotsuga, Tochigi, Japan
关键词
QUALITY-OF-LIFE; BOWEL-DISEASE; 5-AMINOSALICYLIC ACID; PRACTICE GUIDELINES; CLINICAL RELAPSE; RISK-FACTOR; THERAPY; BIOPSY; MESALAZINE; INFLIXIMAB;
D O I
10.1055/a-0869-7619
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and study aims Recently, histological inflammation has been suggested to be an important predictor of sustained remission or relapse of ulcerative colitis (UC). In this study, we retrospectively compared severity of histological inflammation with endoscopic findings in UC patients with mucosal healing (MH) in the remission maintenance phase, and investigated whether histological healing could be a predictor of sustained remission. Patients and methods This study included 166 patients with MH in the remission maintenance phase. Endoscopic evaluation was based on the Mayo endoscopic subscore (MES), and MH was defined as MES 0 or 1. Severity of histological inflammation was graded according to the Matts classification. Patients with Matts 1 and 2 were included in the histological healing (HH) group, and those with Matts 3, 4, and 5, in the non-histological healing (NHH) group.In patients with MH, incidence of relapse was compared and analyzed according to severity of histological inflammation. Results The remission maintenance rate was significantly higher in the MES 0 group than in the MES 1 group ( P =0.004). The rate was significantly higher in the HH group than in the NHH group ( P =0.003). Within the MES 1 group, the rate was significantly higher in the HH subgroup than in the NHH subgroup ( P =0.030). Conclusions This retrospective study suggests that histological healing can be a predictor of sustained remission in UC patients, and examination of histological inflammation provides useful information for long-term management of UC, particularly in patients with MES 1.
引用
收藏
页码:E568 / E575
页数:8
相关论文
共 50 条
  • [41] Tacrolimus for Remission Induction and Maintenance Therapy in Patients with Ulcerative Colitis: A Retrospective Evaluation Study
    Ito, Ayumi
    Iizuka, Bunei
    Omori, Teppei
    Nakamura, Shinichi
    Tokushige, Katsutoshi
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2016, 2016
  • [42] Combined Histo-endoscopic Remission but not Endoscopic Healing Alone in Ulcerative Colitis is Associated with a Mucosal Transcriptional Profile Resembling Healthy Mucosa
    Hernandez-Rocha, Cristian
    Nayeri, Shadi
    Turpin, Williams
    Steel, Mike
    Borowski, Krzysztof
    Stempak, Joanne M.
    Conner, James
    Silverberg, Mark S.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 (07): : 1020 - 1029
  • [43] Mesalazine in left-sided ulcerative colitis: Efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing
    Bokemeyer, Bernd
    Hommes, Daan
    Gill, Ivo
    Broberg, Per
    Dignass, Axel
    JOURNAL OF CROHNS & COLITIS, 2012, 6 (04): : 476 - 482
  • [44] Real-World Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients: A Retrospective Cohort Study
    State, Monica
    Balanescu, Paul
    Voiosu, Theodor
    Bengus, Andreea
    Voiosu, Andrei
    Coman, Andrei
    Mustatea, Petronel
    Negreanu, Lucian
    Mateescu, Radu Bogdan
    Popp, Cristiana
    BIOMEDICINES, 2023, 11 (07)
  • [45] Prostaglandin E-major urinary metabolite diagnoses mucosal healing in patients with ulcerative colitis in remission phase
    Sakurai, Toshiyuki
    Akita, Yoshihiro
    Miyashita, Haruna
    Miyazaki, Ryosuke
    Maruyama, Yuki
    Saito, Tomoko
    Shimada, Mariko
    Yamasaki, Takuji
    Arhihiro, Seiji
    Kato, Tomohiro
    Matsuura, Tomokazu
    Ikegami, Masahiro
    Okayasu, Isao
    Saruta, Masayuki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 (05) : 847 - 854
  • [46] A 'REAL WORLD' RETROSPECTIVE MULTICENTRE STUDY COMPARING INFLIXIMAB AND ADALIMUMAB FOR THE MAINTENANCE OF REMISSION IN ULCERATIVE COLITIS
    Kronsten, Victoria T.
    Colwill, Michael
    Nayeemuddin, Shadab
    Limdi, Jimmy K.
    Selinger, Christian P.
    Scott, Glyn
    Al-Hillawi, Lulia
    Salehi, Shayon
    Blaker, Paul
    Chung-Faye, Guy
    Kent, Alexandra
    Dubois, Patrick
    Hayee, Bu
    GASTROENTEROLOGY, 2018, 154 (06) : S835 - S835
  • [47] HISTOLOGIC INFLAMMATION DEFINED BY THE ROBARTS HISTOPATHOLOGIC INDEX MAY PREDICT FUTURE CLINICAL RELAPSE IN ULCERATIVE COLITIS PATIENTS IN ENDOSCOPIC REMISSION
    George, Lauren
    Feldman, Harris
    Hine, Ashley M.
    Zullow, Samantha
    Stashek, Kristen M.
    Sun, Katherine
    Sarkar, Suparna A.
    Abutaleb, Ameer
    Hudesman, David
    Axelrad, Jordan E.
    Cross, Raymond
    GASTROENTEROLOGY, 2020, 158 (06) : S709 - S709
  • [48] Endoscopic score vs. faecal biomarkers for predicting relapse in patients with ulcerative colitis after clinical remission and mucosal healing
    Yamamoto, T.
    Shimoyama, T.
    Umegae, S.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S225 - S226
  • [49] Endoscopic score vs. fecal biomarkers for predicting relapse in patients with ulcerative colitis after clinical remission and mucosal healing
    Yamamoto, Takayuki
    Shimoyama, Takahiro
    Umegae, Satoru
    Matsumoto, Koichi
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2018, 9
  • [50] Mucosal improvement and histologic healing with amiselimod for active Ulcerative Colitis: a phase 2, randomised, placebo-controlled trial
    Schreiber, S. W.
    Laitman, A. P.
    Heimanson, Z.
    Israel, R. J.
    Lee, J.
    Hanauer, S. B.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1592 - i1593